Hanmi Pharm Co Ltd

Price Chart

Risk-Adjusted Performance

Hanmi Pharm Co Ltd (128940) Price Performance

Hanmi Pharm Co Ltd (128940) trades on KO in KRW. The company is classified in the Healthcare sector under the Drug Manufacturers - Specialty & Generic industry. The stock currently trades at KRW500000.00, up 2.67% from the previous close.

Over the past year, 128940 has traded between a low of KRW234500.00 and a high of KRW626000.00. The stock has gained 107.9% over this period. It is currently 20.1% below its 52-week high.

Hanmi Pharm Co Ltd has a market capitalization of $6.16T, with a price-to-earnings ratio of 50.80 and a dividend yield of 0.41%.

About Hanmi Pharm Co Ltd

Hanmi Pharm. Co., Ltd., a biopharmaceutical company, engages in the manufacture and sale of pharmaceutical products in South Korea, China, Japan, the United States, and internationally. It focuses on research areas with high unmet medical needs, including obesity, metabolism, oncology, and rare diseases. The company's products include Gugutams, a urological combination therapy combining two active ingredients: tamsulosin, a treatment for Obstructive Prostatic Growth (OPG), and tadalafil, a treatment for erectile dysfunction (ED). The company has a research collaboration with MEDIC Life Sciences Inc. to identify cancer biomarkers. The company was founded in 1973 and is based in Hwaseong-si, South Korea.